Lnc RNA NR 2F1‐ AS 1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC 1 via miR‐363

Abstract

Emerging evidence has validated the vital role of long non‐coding RNA (lnc RNA ) in the chemoresistance of cancer treatment. In the present study, we investigate the function of lnc RNA NR 2F1‐ AS 1 on oxaliplatin ( OXA ) resistance of hepatocellular carcinoma ( HCC ) and discover the underlying molecular mechanism. Results revealed that lnc RNA NR 2F1‐ AS 1 was up‐regulated in oxaliplatin‐resistant HCC tissue and cells using microarray analysis and RT ‐ PCR . Meanwhile, ABCC 1 protein was overexpressed in OXA ‐resistant HCC cells (Huh7/ OXA and HepG2/ OXA ). In vitro, NR 2F1‐ AS 1 knockdown reduced the invasion, migration, drug‐resistant gene ( MDR 1, MRP 5, LRP 1) and IC 50 value in Huh7/ OXA and HepG2/ OXA cells. In vivo, NR 2F1‐ AS 1 knockdown decreased the tumour weight of HCC cells. Bioinformatics tools and luciferase reporter assay confirmed miR‐363 targeted the 3′‐ UTR of NR 2F1‐ AS 1 and ABCC 1 mRNA , presenting that NR 2F1‐ AS 1 promoted ABCC 1 expression through endogenous sponging miR‐363. In summary, results conclude that NR 2F1‐ AS 1 regulates HCC OXA resistance through targeting miR‐363‐ ABCC 1 pathway, providing a vital theoretic mechanism and therapeutic target for HCC chemoresistance.

Full text

We don’t show the text of a retracted or withdrawn paper. The record stays, so citations to it can be checked.

References 27

1. 1.
   starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data · 2013

   No notice
2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.
    LncRNA UCA1 in anti-cancer drug resistance · 2017

    No notice
16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

20. 20.
    Long non-coding RNA MALAT1 for promoting metastasis and proliferation by acting as a ceRNA of miR-144-3p in osteosarcoma cells · 2017

    No notice
21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 4

• Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR‐138‐5p and activation of AKT/mTOR signaling pathway · 2021
  Not checked
• Dioscorea Zingiberensis New Saponin Inhibits the Growth of Hepatocellular Carcinoma by Suppressing the Expression of Long Non-coding RNA TCONS-00026762 · 2021
  Not checked
• Role of non-coding RNAs and RNA modifiers in cancer therapy resistance · 2020
  No notice
• The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.